Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes
- PMID: 20943795
- PMCID: PMC2980960
- DOI: 10.3945/ajcn.110.003970
Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes
Abstract
Background: Animal experiments suggest that circulating palmitoleic acid (cis-16:1n-7) from adipocyte de novo fatty acid synthesis may directly regulate insulin resistance and metabolic dysregulation.
Objective: We investigated the independent determinants of circulating palmitoleate in free-living humans and whether palmitoleate is related to lower metabolic risk and the incidence of diabetes.
Design: In a prospective cohort of 3630 US men and women in the Cardiovascular Health Study, plasma phospholipid fatty acids, anthropometric variables, blood lipids, inflammatory markers, and glucose and insulin concentrations were measured between 1992 and 2006 by using standardized methods. Independent determinants of plasma phospholipid palmitoleate and relations of palmitoleate with metabolic risk factors were investigated by using multivariable-adjusted linear regression. Relations with incident diabetes (296 incident cases) were investigated by using Cox proportional hazards.
Results: The mean (± SD) palmitoleate value was 0.49 ± 0.20% (range: 0.11-2.55%) of total fatty acids. Greater body mass index, carbohydrate intake, protein intake, and alcohol use were each independent lifestyle correlates of higher palmitoleate concentrations. In multivariable analyses that adjusted for these factors and other potential confounders, higher palmitoleate concentrations were independently associated with lower LDL cholesterol (P < 0.001), higher HDL cholesterol (P < 0.001), lower total:HDL-cholesterol ratio (P = 0.04), and lower fibrinogen (P < 0.001). However, palmitoleate was also associated with higher triglycerides (P < 0.001) and (in men only) with greater insulin resistance (P < 0.001). Palmitoleate was not significantly associated with incident diabetes.
Conclusions: Adiposity (energy imbalance), carbohydrate consumption, and alcohol use-even within typical ranges-are associated with higher circulating palmitoleate concentrations. Circulating palmitoleate is robustly associated with multiple metabolic risk factors but in mixed directions, perhaps related to divergent lifestyle determinants or endogenous sources (liver, adipose tissue) of fatty acid synthesis.
Similar articles
-
Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study.Ann Intern Med. 2010 Dec 21;153(12):790-9. doi: 10.7326/0003-4819-153-12-201012210-00005. Ann Intern Med. 2010. PMID: 21173413 Free PMC article.
-
trans-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA).Am J Clin Nutr. 2013 Apr;97(4):854-61. doi: 10.3945/ajcn.112.045468. Epub 2013 Feb 13. Am J Clin Nutr. 2013. PMID: 23407305 Free PMC article. Clinical Trial.
-
Serum palmitoleate acts as a lipokine in subjects at high cardiometabolic risk.Nutr Metab Cardiovasc Dis. 2016 Mar;26(3):261-7. doi: 10.1016/j.numecd.2015.12.008. Epub 2015 Dec 28. Nutr Metab Cardiovasc Dis. 2016. PMID: 26817937
-
The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease.Adv Nutr. 2017 Jan 17;8(1):173S-181S. doi: 10.3945/an.115.011130. Print 2017 Jan. Adv Nutr. 2017. PMID: 28096141 Free PMC article. Review.
-
Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes.Curr Drug Targets. 2017;18(6):619-628. doi: 10.2174/1389450117666151209120345. Curr Drug Targets. 2017. PMID: 26648072 Review.
Cited by
-
Prospective association of fatty acids in the de novo lipogenesis pathway with risk of type 2 diabetes: the Cardiovascular Health Study.Am J Clin Nutr. 2015 Jan;101(1):153-63. doi: 10.3945/ajcn.114.092601. Epub 2014 Nov 12. Am J Clin Nutr. 2015. PMID: 25527759 Free PMC article. Clinical Trial.
-
Associations between dietary fatty acid and plasma fatty acid composition in non-alcoholic fatty liver disease: secondary analysis from a randomised trial with a hypoenergetic low-carbohydrate high-fat and intermittent fasting diet.Br J Nutr. 2024 Sep 18;132(4):1-13. doi: 10.1017/S0007114524001673. Online ahead of print. Br J Nutr. 2024. PMID: 39290088 Free PMC article.
-
Plasma levels of 14:0, 16:0, 16:1n-7, and 20:3n-6 are positively associated, but 18:0 and 18:2n-6 are inversely associated with markers of inflammation in young healthy adults.Lipids. 2014 Mar;49(3):255-63. doi: 10.1007/s11745-013-3874-3. Epub 2013 Dec 15. Lipids. 2014. PMID: 24338596
-
Associations between insulin resistance, free fatty acids, and oocyte quality in polycystic ovary syndrome during in vitro fertilization.J Clin Endocrinol Metab. 2014 Nov;99(11):E2269-76. doi: 10.1210/jc.2013-3942. Epub 2014 Apr 2. J Clin Endocrinol Metab. 2014. PMID: 24694334 Free PMC article.
-
Supplementation with Seabuckthorn Oil Augmented in 16:1n-7t Increases Serum Trans-Palmitoleic Acid in Metabolically Healthy Adults: A Randomized Crossover Dose-Escalation Study.J Nutr. 2020 Jun 1;150(6):1388-1396. doi: 10.1093/jn/nxaa060. J Nutr. 2020. PMID: 32140719 Free PMC article. Clinical Trial.
References
-
- Sauma L, Stenkula KG, Kjolhede P, Stralfors P, Soderstrom M, Nystrom FH. PPAR-gamma response element activity in intact primary human adipocytes: effects of fatty acids. Nutrition 2006;22:60–8 - PubMed
-
- Maedler K, Oberholzer J, Bucher P, Spinas GA, Donath MY. Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic beta-cell turnover and function. Diabetes 2003;52:726–33 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- DK71507-04/DK/NIDDK NIH HHS/United States
- N01-HC-85085/HC/NHLBI NIH HHS/United States
- R01 HL085710/HL/NHLBI NIH HHS/United States
- R01-HL085710/HL/NHLBI NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- N01-HC-35129/HC/NHLBI NIH HHS/United States
- DK064360/DK/NIDDK NIH HHS/United States
- N01-HC-55222/HC/NHLBI NIH HHS/United States
- N01-HC-85084/HC/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- U01-HL080295/HL/NHLBI NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- N01-HC-15103/HC/NHLBI NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01-HC-75150/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- N01-HC-45133/HC/NHLBI NIH HHS/United States
- N01-HC-85079/HC/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical